Journal of Clinical Oncology
Articles in this Issue
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in <i>TP53</i> -mutated advanced biliary tract cancer.
4119 Background: TP53 mutations are frequent genetic alterations in cancers and also prevalent in biliary tract cancer (BTC). In non-small cel...
Unraveling the oncogenic potential of p53 amyloids in colorectal cancer.
e15117 Background: Mutations in the p53 tumor suppressor gene are present in more than 50% of cancers, contributing to tumorigenesis. Recent research has...
Real-world experience of fruquintinib in patients with metastatic colorectal cancer: A single-center retrospective study in the United States.
e15613 Background: There is a significant unmet need in patients with refractory metastatic colorectal cancer. Fruquintinib, a selective oral tyrosine kin...
Clinical and pathological insights from 164 patients with ovarian granulosa cell tumors: An 18-year real-world study from China.
e17553 Background: Granulosa cell tumors (GCTs) are the most common type of sex-cord stromal tumors of the ovary. The incidence of this disease is low, an...
Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer.
5000 Background: Standard of care (SoC) for intermediate to high-risk localized prostate cancer (PrCa) includes surgery or...
Safety, efficacy, and pharmacokinetics (PK) of TS-1 combined with cisplatin in advanced cancer patients with severe hepatic dysfunction.
e15001 Background: Advanced cancer patients with severe hepatic dysfunction have limited systemic therapy options due to impaired drug metabolism and incr...
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.
4008 Background: Radical surgical resection represents the only potentially curative treatment option for Biliary Tract Cancer (BTC) and (incidental) Gall...
An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC).
4511 Background: The CM 9ER trial demonstrated increased objective response rate (ORR), progression-free and overall survival in patients with aRCC treate...
Postoperative radiotherapy and survival outcomes in pN2 non-small-cell lung cancer with positive surgical margins: An updated review of the National Cancer Database.
e20010 Background: The role of postoperative radiotherapy (PORT) in non-small-cell lung cancer (NSCLC) remains controversial, particularly in patients wit...
Advancing targeted therapies in oncology: The role of alectinib in managing ALK-positive non-small cell lung cancer.
e20062 Background: Lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC), continues to present a significant global health burden, with research fo...
A digital intervention to enhance engagement with oral oncolytic treatments and assess patient experiences with novel therapies.
11056 Background: Adherence to oral oncolytic therapy influences treatment efficacy and outcomes. Effectively managing adherence requires a clear understa...
Predicting response to durvalumab and olaparib in mTNBC using a novel PD-L1 expression biomarker: A comparison with PD-L1 IHC.
e14612 Background: Immunohistochemistry (IHC) of programmed death ligand-1 (PD-L1) expression is widely used to predict response to Immune Checkpoint Inhi...
Demographic and temporal trends in stroke-related mortality in women with breast cancer in the United States: A retrospective analysis from 1999 to 2020.
e22537 Background: Breast cancer is the second most common cancer worldwide and the most commonly diagnosed cancer in women. In the United States (US), th...
Camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for triple negative breast cancer (TNBC): A single-arm, prospective phase II study (MA-BC-II-026).
e12623 Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by poor prognosis and limited treatment options due to...
Real-world data analysis of clinical characteristics and survival outcomes in Russian patients with NSCLC harboring <i>EGFR</i> mutations.
e20650 Background: EGFR -mutated ( EGFRm ) metastatic non-small cell lung cancer (mNSCLC) is a heterogeneous disease....
Ex vivo 3D micro-tumor testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer.
e17555 Background: While over 200,000 women are diagnosed with high-grade serous ovarian cancer (HGSOC) annually, primary treatment has not changed for de...
Inclusion of gestational surrogacy in oncologist-led fertility counseling at cancer diagnosis: A national survey.
12104 Background: ASCO guidelines recommend that oncologists discuss infertility risks and fertility preservation early with reproductive-aged cancer pati...
Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.
6084 Background: The Neoadjuvant Immuno-Radiotherapy Trial (NIRT-2) is a phase II study, conducted at 2 institutions, that evaluated in patients (pts) wit...
Real-world clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with trifluridine-tipiracil + bevacizumab by performance status.
e15606 Background: The functional status of patients with mCRC is associated with treatment tolerance and survival. The phase 3 SUNLIGHT trial, which show...
Prospective observational study to evaluate efficacy and safety of immunotherapy (IO) in elderly (eld) patients (pts) with non-small cell lung cancer (NSCLC) undergoing comprehensive geriatric assessment (CGA).
e20603 Background: Even though NSCLC prevalence is increasing in the eld population, they are underrepresented in clinical trials, including those involvi...
Predictors of postoperative acute kidney injury in robotic-assisted pulmonary lobectomy.
e20090 Background: Acute Kidney Injury (AKI) has been extensively documented as a predictor of poor perioperative outcomes in thoracic surgery [1,2]. Even...
A first-in-human phase 1 clinical trial of INI-4001, a novel TLR7/8 agonist, in patients with advanced solid tumors.
TPS2703 Background: Inimmune has developed INI-4001, a novel TLR7/8 agonist as an immunotherapy treatment for cancer. Pre-clinically, the lead formulation...
Comparison of adjuvant treatment for intrahepatic cholangiocarcinoma.
e16278 Background: Adjuvant therapy is beneficial to improve the prognosis of intrahepatic cholangiocarcinoma (ICC) patients. Currently, there is a signif...
Pulmonary embolism outcomes across five cancer types: A nationwide analysis.
e20548 Background: Pulmonary embolism (PE) is known to have high mortality and morbidity burden especially in cancer patients. While the association betwe...
Gut microbiome and serum cytokines as biomarkers for pathological complete response (pCR) and recurrence free survival in early locally advanced triple negative breast cancer (LA TNBC) receiving neoadjuvant chemotherapy (NA) and immune checkpoint blocker (ICI): Updated analysis from a pilot study.
e12630 Background: Microbial metabolic pathways are known to influence immunotherapy resistance and these may similarly contribute to resistance in LA TNB...